News >

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

Jason Harris
Published: Monday, Jul 31, 2017

Cameron J. Turtle, PhD

Cameron J. Turtle, PhD
Treatment with CD19 chimeric antigen receptor (CAR)-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia (CLL), according to results recently published in the Journal of Clinical Oncology.

CAR-T cells/kg. Neurotoxicity was reversible in all other patients.
Turtle CJ, Hay KA, Hanafi L, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib [published online July 17, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017. 72.8519.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x